While anti-VEGF therapy has significantly improved outcomes in wet AMD, effective treatments for dry AMD and GA remain limited, underscoring the need for continued research into complement inhibition, gene therapy, and neuroprotection. The gene discussed is VEGFA; the disease is wet macular degeneration.